drugset / Trial / NCT01240863

Study to Evaluate the Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) for Relief of Moderate to Severe Pain in Patients With Osteoarthritis or Low Back Pain Who Require Opioid Treatment for an Extended Period of Time

NCT01240863

Phase 3 Completed 391 enrolled Teva Branded Pharmaceutical Products R&D, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

The primary objective of this study is to evaluate efficacy of hydrocodone extended-release (ER) tablets compared with placebo in alleviating moderate to severe pain in patients with osteoarthritis or low back pain as assessed by the weekly Average Pain Intensity (API) at week 12.

Timeline

Start
2010-11
Primary completion
2011-08
Completion
2011-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Hydrocodone ER Unknown 15 mg
Subject Hydrocodone ER Unknown 30 mg
Subject Hydrocodone ER Unknown 45 mg
Subject Hydrocodone ER Unknown 60 mg
Subject Hydrocodone ER Unknown 90 mg

Indications